0001213900-19-000115.txt : 20190103 0001213900-19-000115.hdr.sgml : 20190103 20190103095326 ACCESSION NUMBER: 0001213900-19-000115 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190103 DATE AS OF CHANGE: 20190103 EFFECTIVENESS DATE: 20190103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elucida Oncology, Inc. CENTRAL INDEX KEY: 0001704594 IRS NUMBER: 471358366 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-293250 FILM NUMBER: 19503825 BUSINESS ADDRESS: STREET 1: 228 PARK AVENUE SOUTH CITY: NEW YORK STATE: NY ZIP: 10003 BUSINESS PHONE: 805-691-9355 MAIL ADDRESS: STREET 1: 228 PARK AVENUE SOUTH CITY: NEW YORK STATE: NY ZIP: 10003 D/A 1 primary_doc.xml X0708 D/A LIVE 0001704594 Elucida Oncology, Inc. 430 E. 29TH STREET, 14TH FLOOR NEW YORK NY NEW YORK 10016 646-701-5391 DELAWARE Claymore Technologies, Inc. None Corporation true 2014 Geno Germano c/o Elucida Oncology, Inc. 430 E. 29TH STREET, 14TH FLOOR New York NY NEW YORK 10016 Executive Officer Director Chief Executive Officer Isaac Blech c/o Elucida Oncology, Inc. 430 E. 29TH STREET, 14TH FLOOR New York NY NEW YORK 10016 Director Tim Boris c/o Elucida Oncology, Inc. 430 E. 29TH STREET, 14TH FLOOR New York NY NEW YORK 10016 Director Robert A. Essner c/o Elucida Oncology, Inc. 430 E. 29TH STREET, 14TH FLOOR New York NY NEW YORK 10016 Director Teresa M. Ressel c/o Elucida Oncology, Inc. 430 E. 29TH STREET, 14TH FLOOR New York NY NEW YORK 10016 Director Robert A. Ruffolo c/o Elucida Oncology, Inc. 430 E. 29TH STREET, 14TH FLOOR New York NY NEW YORK 10016 Director Michael T. Smith c/o Elucida Oncology, Inc. 430 E. 29TH STREET, 14TH FLOOR New York NY NEW YORK 10016 Director Ulrich Wiesner c/o Elucida Oncology, Inc. 430 E. 29TH STREET, 14TH FLOOR New York NY NEW YORK 10016 Director Biotechnology Decline to Disclose 06b true 0001213900-17-009039 2017-08-15 true true true false 25000 Maxim Group LLC 12078 None None 405 LEXINGTON AVENUE NEW YORK NY NEW YORK 10174 All States false 30000000 28094604 1905396 false 170 2764460 true 0 400000 Upon a closing of $15 million in the aggregate, Mr. Edward Rosen, the Company's former CEO, is entitled to the receive up to $400,000 relating to various consulting fees and the reimbursement of expenses pursuant to the terms of his employment agreement. false Elucida Oncology, Inc. /s/ Geno Germano Geno Germano Chief Executive Officer 2019-01-03